Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Top Cited Papers
Open Access
- 6 August 2015
- journal article
- research article
- Published by American Society of Hematology
- Vol. 126 (6), 739-745
- https://doi.org/10.1182/blood-2015-03-635326
Abstract
Key Points Ibrutinib demonstrates durable responses and sustained single-agent activity in relapsed or refractory MCL at median 26.7-month follow-up. Ibrutinib shows a favorable benefit-risk profile over time, with a manageable safety profile.Keywords
This publication has 13 references indexed in Scilit:
- How to manage mantle cell lymphomaLeukemia, 2014
- Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) StudyJournal of Clinical Oncology, 2013
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- Non-Hodgkin lymphoma: the clinician's perspective—a view from the receiving endLaboratory Investigation, 2013
- Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL DatabaseBlood, 2012
- Current treatment standards and emerging strategies in mantle cell lymphomaHematology-American Society Hematology Education Program, 2009
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell LymphomaJournal of Clinical Oncology, 2006
- Tumour lysis syndrome: new therapeutic strategies and classificationBritish Journal of Haematology, 2004
- Role of Bruton's Tyrosine Kinase in B Cell DevelopmentDevelopmental Immunology, 2001